Dose-response relationship between peripheral vascular disease and ingested inorganic arsenic among residents in blackfoot disease endemic villages in Taiwan

Atherosclerosis

Volumn 120, Issue 1-2, 1996, Pages 125-133

  Tseng, Chin Hsiao ^a   Chong, Choon Khim ^c   Chen, Chien Jen ^b   Tai, Tong Yuan ^a  

^a NATIONAL TAIWAN UNIVERSITY HOSPITAL   (Taiwan)

^b NATIONAL TAIWAN UNIVERSITY   (Taiwan)

^c NONE

Author keywords

Arsenic; Blackfoot disease; Peripheral vascular disease; Water pollutant

Indexed keywords

ARSENIC; CHOLESTEROL; TRIACYLGLYCEROL;

ADULT; ARTICLE; BLACKFOOT DISEASE; CIGARETTE SMOKING; CONTROLLED STUDY; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; PERIPHERAL OCCLUSIVE ARTERY DISEASE; PRIORITY JOURNAL; TAIWAN; WATER POLLUTION;

EID: 0030071764     PISSN: 00219150     EISSN: None     Source Type: Journal    
DOI: 10.1016/0021-9150(95)05693-9     Document Type: Article

References (30)

1. Tseng WP. Blackfoot disease in Taiwan: A 30-year follow-up study. Angiology 1989;40:547.
2. Chen CJ, Lin LJ. Human carcinogenicity and atherogenicity induced by chronic exposure to inorganic arsenic. In: Nriagu JO. (ed). Arsenic in the Environment, Part 11: Human Health and Ecosystem Effects. New York: John Wiley & Sons, Inc., 1994;109.
3. Lu FJ, Tsai MH, Ling KH. Studies on fluorescent compounds in drinking water of areas endemic for blackfoot disease. 3. Isolation and identification of fluorescent compounds, J Formos Med Assoc 1978;77:68.
4. Tseng CH, Chen CJ, Lin BJ, Tai TY. Abnormal response of ankle pressure after exercise in seemingly normal subjects living in blackfoot disease-hyperendemic villages in Taiwan. Vasc Surg 1994;28:607.
5. Tseng CH, Chong CK, Chen CJ, Lin BJ, Tai TY. Abnormal peripheral microcirculation in seemingly normal subjects living in blackfoot disease-hyperendemic villages in Taiwan. Int J Microcir 1995;15:21.
6. Blackwell RQ. Estimated total arsenic ingested by residents in the endemic blackfoot area. J Formos Med Assoc 1961;60:1143.
7. Agency for toxic substances and disease registry (ATSDR): Toxicological profile for arsenic. U.S. Environmental Protection Agency (EPA). US 1989;5.
8. Smith AH, Hopenhayn-Rich C, Bates MN, Goeden HM, Hertz-Picciotto I, Duggan HM, Wood R, Kosnett MJ, Smith MT. Cancer risks from arsenic in drinking water. Environ Health Perspect 1992;97:259.
9. Chen CJ, Hsueh YM, Lai MS, Shyu MP, Chen SY, Wu MM, Kuo TL, Tai TY. Increased prevalence of hypertension and long-term arsenic exposure. Hypertension 1995;25:53.
10. Doucette MM, Fylling C, Knighton DR. Amputation prevention in a high-risk population through comprehensive wound-healing protocol. Arch Phys Med Rehabil 1989;70:780.
11. Cheshire NJ, Wolfe JH, Noone MA, Davies L, Drummond M. The economics of femorocrural reconstruction for critical leg ischaemia with and without autologous vein. J Vasc Surg 1992; 15:167.
12. Morrison LB, Bogan IK. Calcification of the vessels in diabetes. J Am Med Assoc 1929;92:1424.
13. Alcolado JC, Pacy PJ, Beevers M, Dodson PM. Risk factors for peripheral vascular disease in hypertensive subjects with type 2 diabetes mellitus. Diabetic Med 1992;9:904.
14. Fowkes FGR, Honsley E, Cawood EHH, MacIntyre CCA, Ruskley CV, Prescott RJ. Edinburgh artery study: prevalence of asymptomatic and symptomatic peripheral arterial disease in the general population. Int J Epidemiol 1991;20:384.
15. Anne BN, Kim ST, Lewis HK. Lower-extremity arterial disease in older hypertensive adults. Arterioscler Thromb 1993;13:555.
16. Tseng CH, Chong CK, Lin BJ, Chen CJ, Tai TY. Atherosclerotic risk factors for peripheral vascular disease in non-insulin-dependent diabetic patients. J Formos Med Assoc 1994;93:663.
17. 2 supply to exercising diabetic feet. Diabetes 1990;39:938.
18. Chen CJ, Lin LJ, Hsueh YM, Chiou HY, Liaw KF, Horng SF, Chiang MH, Tseng CH, Tai TY. Ischemic heart disease induced by ingested inorganic arsenic. In: Chappell WR, Abernathy CO, Cothern CR. (eds). Arsenic Exposure and Health. Northwood: Science and Technology Letters 1994;83-90.
19. 3) on cultured human umbilical vein endothelial cells. J Dermatol 1990;17:599.
20. Lilienfeld DE. Arsenic, geographical isolates, environmental epidemiology and arteriosclerosis. Arteriosclerosis 1988;8:449.
21. Hansen ES. Shared risk factors for cancer and atherosclerosis: a review of the epidemiological evidence. Muta Res 1990;239:163.
22. Lopez S, Miyashita Y, Simons SS Jr. Structurally based, selective interaction of arsenite with steroid receptors. J Biol Chem 1990;165:16039.
23. Lu FJ. Blackfoot disease: arsenic or humic acid? (Letter), Lancet 1990;2:115.
24. Lu FJ, Liu TM. Fluorescent compounds in drinking water of blackfoot disease endemic areas: Animal experimental model. (In Chinese with English abstract). J Formos Med Assoc 1986;85:352.
25. Van Duuren BL, Melchionne S, Seidman I, Pereira MA. Chronic bioassays of chlorinated humic acids in B6C3F1 mice. Environ Health Perspect 1986;69:109.
26. Yang HL, Tu SC, Lu FJ, Chiu HC. Plasma protein C activity is enhanced by arsenic but inhibited by fluorescent humic acid associated with blackfoot disease. Am J Hematol 1994;46:264.
27. Lu FJ, Irgolic KJ, Lin CW, Ling KH, Tung TC. Fluorescent compounds in drinking well water of blackfoot disease endemic areas: Ergotamine in the artesian well water. (In Chinese with English abstract). J Formos Med Assoc 1982;81:1087.
28. Lu FJ, Shih SR, Liu TM, Shown SH. The effect of fluorescent humic substances existing in the well water of blackfoot disease endemic areas in Taiwan on prothrombin time and activated partial thromboplastin time in vitro. Thromb Res 1990;57:747.
29. Lu FJ. Arsenic as a promoter in the effect of humic substances on plasma prothrombin time in vitro. Thromb Res 1990;58:537.
30. Lu FJ, Lee YS. Humic acid: Inhibitor of plasmin. Sci Total Environ 1992;114:135.